ChemoCentryx, Inc. (CCXI)'s CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In ANCA-Associated Diseases By The FDA
6/3/2014 9:09:07 AM
MOUNTAIN VIEW, Calif., June 3, 2014 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) reported today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for CCX168, an orally administered inhibitor that targets the receptor for the complement protein known as C5a (C5aR). The designation is for the treatment of anti-neutrophil cytoplasmic autoantibodies (ANCA) -associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome). CCX168 is currently in the third step of the CLEAR clinical trial in patients with ANCA-associated vasculitis.
Help employers find you! Check out all the jobs and post your resume.
comments powered by